# Cardiovascular Effects of GLP-1 Receptor Activation

Study · id `cardio:ct-nct03101930` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03101930](<https://clinicaltrials.gov/study/NCT03101930>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03101930

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 329 participants.

## Technical summary

Registry record NCT03101930. Randomized; quadruple masking; primary purpose basic science. Start 2017-05-01 (actual); primary completion 2021-06-24 (actual). Results posted on 2022-08-16.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose basic science
- Phase: Phase 4
- Enrolled: 329 participants (enrolled count; ClinicalTrials.gov record NCT03101930, source copy `cardio:ctgov-nct03101930-2022-10-18`, retrieved 2026-10-26)
- Started: 2017-05-01 (actual) (ClinicalTrials.gov record NCT03101930, source copy `cardio:ctgov-nct03101930-2022-10-18`, retrieved 2026-10-26)
- Primary completion: 2021-06-24 (actual) (ClinicalTrials.gov record NCT03101930, source copy `cardio:ctgov-nct03101930-2022-10-18`, retrieved 2026-10-26)
- Completion: 2021-06-24 (actual) (ClinicalTrials.gov record NCT03101930, source copy `cardio:ctgov-nct03101930-2022-10-18`, retrieved 2026-10-26)
- Results first posted: 2022-08-16 (ClinicalTrials.gov record NCT03101930, source copy `cardio:ctgov-nct03101930-2022-10-18`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03101930, source copy `cardio:ctgov-nct03101930-2022-10-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03101930-2022-10-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cardiovascular Effects of GLP-1 Receptor Activation
- Condition: Obesity
- Condition: PreDiabetes
- Intervention (Drug): Liraglutide
- Intervention (Drug): Sitagliptin
- Intervention (Other): hypocaloric diet
- Intervention (Drug): Placebos
- Intervention (Drug): Exendin (9-39)
- Lead sponsor: Vanderbilt University Medical Center
- Lead sponsor class: OTHER
- Collaborator: American Heart Association
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Vanderbilt University Medical Center (`cardio:org-vanderbilt-university-medical-center`)
- Registry lists this organization as a collaborator: American Heart Association (`core:aha`)

## Provenance

Content hash: aecb57b61d5b937cd618d6547c5d58d40421c79a35758704c23f1087f8c6467e
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
